Speaker

Conferences Speaker:

Lecturer

lecture

As a faculty member at both UCLA School of Management in Los Angeles and Northeastern University, he has taught an entrepreneur course that focuses on helping actual university ventures improve their strategies to achieve external funding. The course teaches frameworks for considering target markets, customer segmentation, product design and validations, venture team assessments, as well as business and financial models. The Northeastern University students (~450) have applied these methods to improve the business plans for new ventures in the past four years. Working in teams, students design and administer customer surveys, create detailed financial projections, and create investor packages. This will include a due diligence package, a term sheet, and a power-point presentation for investors. University companies (~85) have been taken from multiple areas across the campus, including different technologies and services. Overall, the course is a practicum on what it takes to get new venture concepts funded and launched from the perspective of the entrepreneur, the customer, and the investor.

lecture

Education Course (Entrepreneurial Strategies for Technology Ventures)

  • UCLA, School of Management, MBA Program in Los Angeles, CA
  • Northeastern University School of Business in Boston, Ma.

This course focuses on helping technology ventures define and improve their strategies and tactics to achieve external funding. The course teaches frameworks for developing a growth-focused product and service strategy, how to grow and evolve a startup team, creating scalable business models, and early stage, successive round venture finance.

Students (~450 to date) have apply these methods to improve the business plans for early stage technology ventures (~83 university companies). Working in teams, students will provide the CEO at the end of term; a business plan, create financial projections and an investor package for early stage ventures, with specific assessments of customer focus and needs, intellectual property, new product line and technology strategy, and business model design. Company projects have been taken from multiple areas from across University and from alumni in the fields of IT, healthcare and life sciences. Deliverables will include a business plan, a customer survey of their product, an investor’s due diligence package, a term sheet, and a PowerPoint presentation for investors. Overall, the course is a practicum on what it takes to get new venture concepts funded and scaled from the perspective of the entrepreneur, the investor and what the customer wants.

Selected (135) Cancer Science Papers:

  • Scanlon K.J., Newman, E.M., Lu Y., and Priest D.G. Biochemical basis for cisplatin and 5-Fura synergism in human carcinoma cells. Proc. Nat’l.
    Acad. Sci. (USA) 83:8923-8925, 1986.
  • Scanlon, K.J. and Kashani-Sabet, M. Elevated expression of dTMP synthase cycle genes in cisplatin-resistant human carcinoma cells. Proc.
    Nat’l. Acad. Sci (USA) 85:650-653, 1988.
  • Lu, Y., Han, J., and Scanlon, K.J. Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J. Biol. Chem.
    263:4891-4894, 1988.
  • Kashani-Sabet, M., Rossi, J.J., Lu, Y., Ma, J.X., Chen, J., Miyachi, H., and Scanlon, K.J. Detection of drug resistance in tumors by PCR assay. Cancer
    Research 48:5775-5778, 1988.
  • Scanlon, K.J., Kashani-Sabet, M., and Sowers, L. Overexpression of DNA replication and repair enzymes in resistant cells and circumvention by
    AZT. Cancer Comm. 1:269-275, 1989.
  • Scanlon, K.J., Funato, T., Pezeshki, B., Tone, T., and Sowers, L.C. Potentiation of azidothymidine cytotoxicity in resistant carcinoma cells.
    Cancer Comm. 2:339-344, 1990.
  • Kashani-Sabet, M., Wang, W., and Scanlon, K.J. Cyclosporin A suppresses cisplatin-induced c- fos gene expression in ovarian carcinoma cells.
    J. Biol. Chem. 263:11285-11288, 1990.
  • Scanlon, K.J., Jiao, L., Funato, T., Wang, W., Tone, T., Rossi, J.J., and Kashani-Sabet, M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene
    expression of DNA synthesis enzymes and metallothionein. Proc. Nat’l. Acad. Sci. (USA) 88:10592-10595, 1991.
  • Kashani-Sabet, M., Funato, T., Tone, T., Jiao, L., Wang, W., Yoshida, E. Wu, A.M., Moreno, J.G., Traweek, S.T., Ahlering, T.E., and Scanlon, K.J. Reversal
    of the malignant phenotype by an anti-ras ribozymes. Antisense Res. & Dev., 2:3-15, 1992.
  • Kashani-Sabet, M., Funato, T., Florenes, V.A., Fodstad, O., and Scanlon, K.J. Suppression of the neoplastic phenotype in vivo by an anti-ras
    ribozyme. Cancer Research 54:900-902, 1994.
  • Scanlon, K.J., Ishida, H., and Kashani-Sabet, M. Reversal of the multi-drug resistant phenotype by a fos ribozyme. Proc. Nat’l. Acad. Sci. (USA)
    91:11123-11127, 1994.
  • LSFeng, M., Cabrera, G., Scanlon, K.J., and Curiel, D. Neoplastic reversion accomplished by adenoviral-mediated delivery
    of an anti-ras ribozyme. Cancer Research 55:2024-228, 1995.
  • Scanlon, K.J., Ohta, Y., Ishida, H., Kijima, H., Ohkawa, T., Kaminiski, A., Tsai, J., Horng, G. and Kashani-Sabet, M. Oligonucleotide-mediated modulation of mammalian gene expression. FASEB Jour. 9:1288-1296, 1995.
  • Ohta, Y., Kijima, H., Ohkawa, T., Kashani-Sabet, M., and Scanlon, K.J. Suppression of the malignant phenotype of melanoma cells by anti-oncogene
    ribozymes. J. Invest. Derm. 106:275-280, 1996.

Let’s talk about your next big project.

Feel free to contact me by filling out this form or you can email me at info@kjscanlon.com

Kevin J. Scanlon, Ph.D.
Boston, MA 02123